Mesenchymal Stem Cell Concentration Using Antibody Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods fail to sufficiently concentrate mesenchymal stem cells from cord blood, resulting in samples with high foreign matter content and inadequate cell numbers, making it impossible to obtain a sufficient number of undifferentiated mesenchymal stem cells for medical applications.
Innovation Solution
Concentrating cord blood-derived mesenchymal stem cells using antibodies specifically recognizing blood cells, followed by culturing in a medium containing SHH, FGF1, or FGF2 with SCF to maintain undifferentiated growth and promote cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods (HES, ficoll, filter) are used to concentrate mesenchymal stem cells, then erythrocytes are removed from blood, but the concentration of mesenchymal stem cells remains insufficient and foreign matter content remains high
Solution Approach 1:
The patent extracts and removes specific blood cell types (erythrocytes and other unwanted cells) from cord blood using antibodies that specifically recognize these cells. This selective extraction allows mesenchymal stem cells to be concentrated while removing foreign matter, directly resolving the contradiction between cell concentration and purity.
Solution Approach 2:
The patent introduces antibodies as intermediary substances that mediate between the cord blood sample and the separation process. These antibodies specifically bind to target blood cells, enabling selective removal while preserving mesenchymal stem cells, thus achieving both high concentration and low foreign matter content.
2Quantity of substance
If conventional concentration methods are used, then some cell separation is achieved, but adequate numbers of undifferentiated mesenchymal stem cells cannot be obtained
Solution Approach 1:
The patent changes the chemical parameters of the culture medium by adding specific growth factors (SCF, FGF1, or FGF2, and SHH) to maintain the undifferentiated state of mesenchymal stem cells during culture. This parameter change enables both adequate cell numbers and maintenance of stem cell characteristics.
Solution Approach 2:
The patent performs preliminary concentration of mesenchymal stem cells using antibody-based methods before culture, ensuring that only target cells are subjected to the culture process. This preliminary action increases the efficiency of obtaining adequate numbers of undifferentiated cells by starting with a pre-enriched population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method efficiently obtains a large number of undifferentiated mesenchymal stem cells from a small volume of cord blood, suitable for regenerative medicine applications, as demonstrated by significant cell growth and maintenance of stem cell characteristics over 14 days.
Implementation Method 1
concentrating cord blood-derived mesenchymal stem cells with use of an antibody that specifically recognizes blood cells
Implementation Method 2
culturing the concentrated sample thus generated in a medium containing SHH, FGF1, or FGF2, wherein the medium further contains SCF
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method in accordance with the present invention includes the steps of: concentrating cord blood-derived mesenchymal stem cells; and causing the mesenchymal stem cells thus concentrated to grow with use of a particular factor while maintaining undifferentiated state of the mesenchymal stem cells.